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Headache is felt, at some time, by nearly everybody, and
almost half the world’s adults at any point in time have
recent personal experience of one or more headache dis-
orders [1]. In the Global Burden of Disease Study, updated
in 2004, migraine on its own accounted for 1.3% of all
years of life lost to disability worldwide [2]. Other head-
ache disorders, collectively, may be responsible for a
similar burden [1]. Yet, much is unknown about the public-
health impact of these disorders. Not only is our view
incomplete of the global burden attributable to headache
disorders, but also our knowledge of health-care resource
allocation to them is scant.
The World Health Organization (WHO) initiated Project
Atlas with the objective of collecting, compiling and dis-
seminating relevant information on health-care resources in
countries. Within Project Atlas, information has been gath-
ered for various domains of mental and neurological services
and conditions of public-health priority. The Atlas of
Headache Disorders and Resources in the World 2011 [3],
an important addition to this series, presents information on
the burden of headache disorders and the resources available
to reduce them. The information was acquired by WHO in
collaboration with Lifting The Burden (an international non-
governmental organization in official relation with WHO) as
a project within the Global Campaign against Headache [4].
Most of the data were obtained through a questionnaire
survey of neurologists, general practitioners and patients’
advocates from 101 countries, representing 86% of the
world’s population. Epidemiological data were compiled
from published studies through a systematic review [1], and
supplemented by data gathered in population-based studies
undertaken within the Global Campaign [5].
What were the findings of this first global enquiry into
these matters? They were that headache disorders are
ubiquitous, prevalent, disabling and, although largely
treatable, under-recognized, under-diagnosed and under-
treated. Very large numbers of people disabled by head-
ache do not receive effective health care, so that illness that
could be relieved is not, and burdens, both individual and
societal, persist. The barriers responsible for this vary
throughout the world, but poor awareness in the context of
limited resources generally—and in health care in partic-
ular—is high among them everywhere.
In summary, the findings illuminate worldwide neglect of
a major public-health problem, and reveal the inadequacies
of responses to it in countries throughout the world. The
implications of these findings show the way forward.
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Knowledge gaps must be filled
Despite that headache disorders impose such disability
worldwide, knowledge to inform policy is still incomplete.
Further well-conducted epidemiological studies, incorpo-
rating population-based measures of individual and societal
burdens, are needed in many countries, and especially
those that are resource-poor.
Health care for headache disorders must be improved
Worldwide, about 50% of people with headache are pri-
marily self-treating, and not in contact with any health
professionals. This is reasonable: much tension-type
headache and some migraine manifests only as infrequent
and/or mild attacks. On the other hand, if diagnosis rate
reflects quality and reach of headache services, which is
likely, there is much room for improvement in all regions.
At best the diagnosis rate is 40%, meaning that 60% of
people with headache disorders are not properly diagnosed.
For medication-overuse headache, a high cause of dis-
ability that is both preventable and remediable, the diag-
nosis rate is 10%. Since this disorder is unlikely to resolve
without medical care, this is a failure of health care that has
important adverse health and economic consequences.
Guidelines for diagnosis and treatment will support
better management, particularly by non-experts in primary
care. In many countries that lack them—which are, espe-
cially, low-income countries —there is a low-cost oppor-
tunity for substantial service improvement.
Again worldwide, the Atlas reveals high rates of
investigations performed to support diagnosis. This is not
expected, since headache disorders mostly do not require
investigations, either for diagnosis or assessment. Sub-
stantial reductions are possible, with resource savings that
can be channelled into better medical care.
Assessment of impact of headache is part of manage-
ment, needed especially where resources are limited in
order to direct them efficiently. Existing assessment
instruments are easy to use, but are employed in only a
quarter of responding countries. There is a large and low-
cost opportunity for improvement through their wider
usage, particularly in resource-poor countries.
Many effective drugs exist for headache disorders, but
countries in all income categories identify lack of access to
them as a barrier to best management. In particular, triptans
should be used in preference to ergotamine, which not only
has inferior efficacy but also raises concern over toxicity,
accumulation and overuse potential [6]. For these reasons,
triptans need to be more widely available.
Reimbursement of drug costs is, for many people, the
key to better access to drugs. Reimbursement has obvious
societal cost implications, but these must be considered in
full. Given the cost-effectiveness of most drugs for head-
ache, policies of wider reimbursement appear sensible from
a societal perspective.
Headache services must be organized
The headache disorders that cause most population ill-
health are migraine, tension-type headache and medica-
tion-overuse headache. It is primarily for these disorders
that headache services throughout the world must cater.
Headache services need to be delivered countrywide,
efficiently and equitably to a very large number of people
who stand to benefit from them. Organization of services to
achieve this is clearly a challenge, perhaps with no single,
complete and universally appropriate solution, but always
their basis must be in primary care. This is where the great
majority of people with headache are and should be man-
aged. The proportion of 10% currently seen by specialists
is far too great: specialist services are required by and
should be reserved for only the very small minority who
need them.
A strong efficiency-based argument therefore exists for
expanding primary-care management of headache disor-
ders, and this is particularly so in countries where health-
service reforms are, generally, shifting priority towards
primary care.
Education is central to remedial action
Lack of education was seen as the key issue impeding good
management of headache, and better professional educa-
tion ranked far above all other proposals for change (75%
of the countries that responded to the enquiry). Accordance
of low priority to headache disorders means they are given
little educational emphasis in medical training which
translates later into ineffective management and poor out-
comes. Change can only follow recognition of the amount
of ill-health these disorders cause, and reassessment of
priority accordingly.
Education is required at multiple levels. Most impor-
tantly, health-care providers need better knowledge of how
to diagnose and treat the small number of headache dis-
orders that are of public-health importance. This better
knowledge will improve usage of available treatments,
produce better outcomes, avoid wastage and reduce overall
costs.
Because most headache should be treated in primary
care, emphasis should first be on undergraduate training, in
medical schools, requiring changes to the undergraduate
curriculum. At present, worldwide, just four hours are
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committed to headache disorders in courses lasting
4–6 years. Second, it should be on continuing medical
education for general practitioners.
As noted earlier, worldwide about 50% of people with
headache are primarily self-treating, and not in contact
with any health professionals. Therefore, education of
people with headache about how to treat their headaches
effectively and efficiently is of considerable public-health
importance. In better-resourced countries especially, one
focus of education should be the avoidance of medication
overuse and its consequence of medication-overuse head-
ache, itself a high cause of disability.
National professional organizations should be
supported
National professional headache organizations for headache
disorders exist in two-thirds of countries that responded,
with a very marked difference between high- and upper
middle-income (71–76%) and low-income countries (16%).
The true figures may be much lower, as respondents were
much more readily identified in countries with such organi-
zations. But where these organizations exist, they have clear
roles in promoting education, producing locally relevant
management aids, including guidelines, and importing
knowledge and international standards through links to inter-
national groups. Support for the establishment and mainte-
nance of these organizations appears highly worthwhile.
Political will is needed
For all of these, if they are to be effective ways forward,
there is an urgent need for political recognition that the
problem exists, and that it demands remedial action. The
Atlas of Headache Disorders is intended to have this effect.
Apart from the humanitarian burden of pain and debility
and the public ill-health arising from headache, the finan-
cial costs of headache disorders to society through lost
productivity are enormous [7]—far greater than the health-care
expenditure on headache in any country [8]. Investment in
well-organized headache services, supported by education,
is highly sensible, and may well be cost-saving overall.
Governments need to take note.
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